2021
Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias
Schnell PM, Lustberg MB, Henry NL. Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias. JNCI Cancer Spectrum 2021, 5: pkab018. PMID: 33842832, PMCID: PMC8023424, DOI: 10.1093/jncics/pkab018.Peer-Reviewed Original ResearchConceptsPatient-perceived benefitsAdverse eventsBrief Pain Inventory-Short FormAromatase Inhibitor–Associated ArthralgiaDuloxetine-treated patientsOriginal primary outcomeDouble-blind trialLow-grade toxicityEffect of duloxetineSubgroup of patientsAverage painComparable patientsAppropriate patientsPrimary outcomeMusculoskeletal symptomsBreast cancerPlaceboDuloxetineSide effectsFunctional assessmentPatientsSecondary analysisFavorable effectTreatmentPerceptions of benefits
2017
THU0062 Novel animal model of aromatase inhibitor-induced arthralgia suggests an estrogen-independent inflammatory mechanism
Young N, Thomas E, Snoad B, Sharma J, Mobeen M, DeVries A, Bratasz A, Lustberg M, Jarjour W, Reinbolt R. THU0062 Novel animal model of aromatase inhibitor-induced arthralgia suggests an estrogen-independent inflammatory mechanism. Annals Of The Rheumatic Diseases 2017, 76: 222. DOI: 10.1136/annrheumdis-2017-eular.5424.Peer-Reviewed Original ResearchBreast cancer patientsEarly-stage breast cancer patientsAromatase inhibitor-related arthralgiaStage breast cancer patientsBreast cancer researchSerum cytokine levelsBreast cancer survivorsAromatase inhibitorsNovel animal modelInflammatory mechanismsCancer patientsCytokine levelsCancer survivorsMusculoskeletal symptomsRisk factorsHistopathological analysisProspective characterizationAI treatmentHormone receptor-positive breast cancer patientsAnimal modelsReceptor-positive breast cancer patientsNFκB activationAromatase inhibitor-induced arthralgiaBioluminescent imagingKnee joint